Comparative effectiveness of combination therapy with SGLT ‐2 inhibitors and GLP ‐1 RAs compared with SGLT ‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study
Main finding · All-cause mortalityResult — go to the resultHazard ratio 0.71 95% CI 0.63–0.80Authors' conclusion
In this large real-world cohort, combination therapy with SGLT-2 inhibitors and GLP-1 RAs was associated with a lower hazard of all-cause mortality, while most secondary cardiorenal outcomes showed generally favourable but imprecise estimates. These findings suggest that sustained concurrent use of both drug classes may offer meaningful clinical benefits in routine practice, although residual confounding cannot be fully excluded.
Study context
- Population
- Individuals with T2D in nationwide BARMER health claims data, enrolled 2013–2023, follow-up possible including 202421,664 matched pairs
- Exposure
- SGLT2i + GLP-1 RA combination therapy vs continued SGLT2i
- Outcome
- All-cause mortality
- Follow-up
- Median 1.3 years
Methodological detailsnationwide health claims data, hybrid exposure sets, time-conditional propensity score matched
- Nationwide health claims data
- Hybrid exposure sets
- Time-conditional propensity score matched
Main finding
As reported in the abstract
Hazard ratio
0.71
95% CI 0.63–0.80
Combination therapyvs SGLT2i continuers
HR 0.71 (95% CI 0.63–0.80)
Observational data: associations, not effects.
Secondary outcomes
Modified cardiovascular composite (all-cause mortality, MI, stroke)
- Hazard reduction, HR
- 0.81 (0.74-0.88) (95% CI)
Heart failure
- Hazard reduction, HR
- 0.78 (0.68-0.89) (95% CI)
Original publication
Comparative effectiveness of combination therapy with SGLT ‐2 inhibitors and GLP ‐1 RAs compared with SGLT ‐2 inhibitors in individuals with type 2 diabetes: A prevalent new‐user cohort study. Diabetes Obes Metab. Published 22 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →